Below are the most recent publications written about "Albumins" by people in Profiles.
-
Austermeier S, Cheng KO, Dietschmann A, Vascelli G, Montaño DE, Hitzler SUJ, Skurk KS, Fernández-Fernández C, Saloni S, Westermann S, Jaeger M, Jablonowski N, Wisgott S, Elshafee O, Brachelente C, de Graaf DM, Próchnicki T, Latz E, Wirtz S, Becker C, Renga G, Oikonomou V, Hube B, Donders GGG, Pekmezovic M, Zelante T, Gresnigt MS. Local albumin excess exacerbates Candida albicans-induced inflammasome activation linked with hyperinflammation during vulvovaginal candidiasis. Nat Commun. 2026 Oct 29; 17(1).
-
Fakih HH, Ohara M, Summers A, Sarli SL, Kelly K, Gagnon R, Maru B, Bramato B, Khvorova A, Watts JK. Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system. Nucleic Acids Res. 2026 Sep 22; 54(18).
-
Tocheny CE, Buchwald JE, Dahlke CD, Fakih HH, Morgan JS, Summers A, Silva CA, Jackson SO, Lee JS, Card MA, Echeverria D, Peterson C, Mercurio AM, Khvorova A, Shaw LM. Therapeutic delivery of albumin-binding siRNA targeting IRS2 to diverse cell types reduces mammary tumor growth. Mol Ther. 2026 05 06; 34(5):2963-2982.
-
Liu GY, Ye YF, Jiang YF, Chen GJ, Xia WX, Huang YS, Gao TS, Liu YM, Hou YT, Li JF, Liu JH, Lu N, Chen CL, Ke LR, Liang H, Bei WX, Li WZ, Dong SH, Liu Q, Xie C, Yao HR, Xiang YQ. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ. 2024 06 19; 385:e077890.
-
Verma A, Schmidt IM, Claudel S, Palsson R, Waikar SS, Srivastava A. Association of Albuminuria With Chronic Kidney Disease Progression in Persons With Chronic Kidney Disease and Normoalbuminuria : A Cohort Study. Ann Intern Med. 2024 04; 177(4):467-475.
-
Asohan J, Fakih HH, Das T, Sleiman HF. Control of the Assembly and Disassembly of Spherical Nucleic Acids Is Critical for Enhanced Gene Silencing. ACS Nano. 2024 02 06; 18(5):3996-4007.
-
Srivastava A, Amodu A, Liu J, Verma A, Mothi SS, Palsson R, Stillman IE, Kestenbaum BR, Waikar SS. The Associations of Urine Albumin-Protein Ratio With Histopathologic Lesions and Clinicopathologic Diagnoses in Individuals With Kidney Disease. Am J Kidney Dis. 2024 04; 83(4):557-560.
-
Perez K, Chiarella AM, Cleary JM, Horick N, Weekes C, Abrams T, Blaszkowsky L, Enzinger P, Giannakis M, Goyal L, Meyerhardt JA, Rubinson D, Yurgelun MB, Goessling W, Giantonio BJ, Brais L, Germon V, Stonely D, Raghavan S, Bakir B, Das K, Pitarresi JR, Aguirre AJ, Needle M, Rustgi AK, Wolpin BM. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Oncologist. 2023 05 08; 28(5):425-432.
-
Paredes de la Fuente R, Doolin JW, Peters ML. Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab. BMJ Case Rep. 2023 Feb 06; 16(2).
-
Hemond CC, Baek J, Ionete C, Reich DS. Paramagnetic rim lesions are associated with pathogenic CSF profiles and worse clinical status in multiple sclerosis: A retrospective cross-sectional study. Mult Scler. 2022 Nov; 28(13):2046-2056.